148901-69-3

Basic information

• Product Name: Ethyl (E)-7-[4-(4'-fluorophenyl)-2-(cyclopropyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate
• Synonyms: ETHYL (E)-7-[4-(4''-FLUOROPHENYL)-2-(CYCLOPROPYL)-3-QUINOLINYL]-5-HYDROXY-3-OXO-6-HEPTENOATE;(E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoic acid ethyl ester;Ethyl (E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate;Pitavastatin 3-Oxo Ethyl Ester;Ethyl(E)-(5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)-5-hydroxy-3-oxo-3-quinolinyl]-hept-6-enoate;(E)-Ethyl 7-(2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl)-5-hydroxy-3-oxohept-6-enoate;6-Heptenoic acid, 7- 2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl -5-hydroxy-3-oxo-, ethyl ester, (E)-;3-Oxo Pitavastatin Ethyl Ester
• CAS NO: 148901-69-3
• Molecular Formula: C₂₇H₂₆FNO₄
• Molecular Weight: 447.5
• EINECS: 1312995-182-4
• Mol File: 148901-69-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 651.3 °C at 760 mmHg
• Flash Point: 347.7 °C
• Appearance: /
• Density: 1.268
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 10.30±0.46(Predicted)
• CAS DataBase Reference: Ethyl (E)-7-[4-(4'-fluorophenyl)-2-(cyclopropyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl (E)-7-[4-(4'-fluorophenyl)-2-(cyclopropyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate(148901-69-3)
• EPA Substance Registry System: Ethyl (E)-7-[4-(4'-fluorophenyl)-2-(cyclopropyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate(148901-69-3)

Safety Data

• Hazardous Substances Data: 148901-69-3(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 148901-69-3 differently. You can refer to the following data:
1. (E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoic Acid Ethyl Ester is an impurity of Pitavastatin (P531000), a competitive inhibitor of HMG-CoA reductase and antilipemi c agent.
2. (E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoic Acid Ethyl Ester is an impurity of Pitavastatin (P531000), a competitive inhibitor of HMG-CoA reductase and antilipemic agent.

Upstream product

• 141-97-9 ethyl acetoacetate 
• 148901-68-2 (E)-3-[2-cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-propenal 
• 121660-11-5 2-cyclopropyl-4-(4-fluorophenyl)-3-(hydroxymethyl)quinoline 
• 121660-37-5 2-cyclopropyl-4-(4-fluorophenyl)-3-formylquinoline 
• 166803-31-2 (E)-7-[2-cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dioxo-hept-6-enoic acid ethyl ester 
• 391681-95-1 2-cyclopropyl-3-(3-ethoxy-1-hydroxy-2-propenyl)-4-(4-fluorophenyl)quinoline 
• 121660-18-2 [2-cyclopropyl-4-(4-fluoro-phenyl)-6,7-dimethoxy-quinolin-3-yl]-methanol 
• 121660-43-3 2-cyclopropyl-4-(4-fluoro-phenyl)-6,7-dimethoxy-quinoline-3-carbaldehyde 
• 121659-86-7 methyl 4-(4'-fluorophenyl)-2-cyclopropylquinoline-3-carboxylate 
• 256431-72-8 (E)-3-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-2-propenenitrile 
• 32249-35-7 methyl 3-cyclopropyl-3-oxopropanoate 
• 3800-06-4 2-amino-4'-fluorobenzophenone 

Downstream Products

• 172336-32-2 (±)-E-3,5-dihydroxy-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-6-heptenoic acid ethyl ester 
• 172336-32-2 ethyl (E)-3,5-dihydroxy-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]hept-6-enoate 
• 166803-31-2 (E)-7-[2-cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dioxo-hept-6-enoic acid ethyl ester 
• 147526-32-7 pitavastatin 
• 254452-86-3 (E)-(3S,5R)-7-[2-Cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dihydroxy-hept-6-enoic acid 

Relevant articles and documents

A pitavastatin calcium bulk drug intermediate preparation method

The invention discloses a preparing method for a pitavastatin calcium bulk drug intermediate. The intermediate is (+/-) E-6-[2- cyclopropyl-4-(4-fluorophenyl)-quinoline-3-phenyl vinyl]-4-hydroxy-3,4,5,6-tetralin-valerolactone. The method comprises the ste

Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors

A series of quinoline-based 3,5-dihydroxyheptenoic acid derivatives were synthesized from quinolinecarboxylic acid esters by homologation, aldol condensation with ethyl acetoacetate dianion, and reduction of 3-hydroxyketone to evaluate their ability to inhibit the enzyme HMG-CoA reductase in vitro. In agreement with previous literature, a strict structural requirement exists on the external ring, and 4-fluorophenyl is the most active in this system. For the central ring, substitution on positions 6, 7, and 8 of the central quinoline nucleus moderately affected the potency, whereas the alkyl side chain on the 2-position had a more pronounced influence on activity. Among the derivatives, NK-104 (pitavastatin calcium), which has a cyclopropyl group as the alkyl side chain, showed the greatest potency. We found that further modulation and improvement in potency at inhibiting HMG-CoA reductase was obtained by having the optimal substituents flanking the desmethylmevalonic acid portion, that is, 4-fluorophenyl and cyclopropyl, instead of the usual isopropyl group.